drugset / Trial / NCT07313852
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
Phase 1/2
Not yet recruiting
26 enrolled
Memorial Sloan Kettering Cancer Center
Amgen · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Timeline
- Start
- 2026-06
- Primary completion
- 2029-01
- Completion
- 2029-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Blinatumomab | Monoclonal antibody | — | Subcutaneous |